If you have been reading about carcinogenicity and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport; not approved as medicine | Listed by WADA at all times. |
| Common synonyms | GW501516, GW-501516, endurobol | Cardarine is a colloquial name. |
| Typical analytical method | LC-MS/MS | Detects parent compound and metabolites. |
| Common test matrix | Urine | Blood and dried blood spots also possible. |
| Legal classification | Varies by country | Often treated as unapproved drug or research chemical. |
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
== Symbols and units == The IUPAC-recommended symbols for mass and charge are m and Q, respectively, however using a lowercase q for charge is also very common. Charge is a scalar property, meaning that it can be either positive (+) or negative (−). The Coulomb (C) is the SI unit of charge; however, other units can be used, such as expressing charge in terms of the elementary charge (e). The SI unit of the physical quantity m/Q is kilogram per coulomb.
== History == The early 19th century witnessed a sharp increase in the demand for natural ice during the summer months, particularly among breweries producing lager. Due to the advent of railways and steam ships, natural ice was able to be transported efficiently and thus became more readily attainable. To meet the demand for ice, suppliers began investing in methods of producing ice by artificial means. Though it was first documented by Oliver Evans, it was Jacob Perkins, an American working in England, who first patented a machine using the vapour-compression cycle to produce a cooling effect in 1835. In 1855, the first industrial-scale compression machines were developed by James Harrison. Following this, Ferdinand Carré invented the absorption device in 1859. This was then rendered obsolete by the invention of the vapor compression refrigerator invented by French engineer Charles Tellier in 1885, the basic principles of which are used today. To support the development of refrigeration technologies and in view of the economic development potential they represented, the IIR was created in several stages:
The main SF unit in South Vietnam was the 5th Special Forces Group (Airborne). SF soldiers assigned to the 5th Group earned sixteen Medals of Honor in Vietnam, making it the most prominently decorated unit for its size in that conflict. The unit was also awarded the coveted Presidential Unit Citation for extraordinary heroism during the Vietnam War from 1 November 1966 – 31 January 1968. Army Special Forces personnel also played predominant roles in the highly secret, covert, multi-service Military Assistance Command Vietnam Studies and Observation Group (MACV-SOG), with an extraordinarily large number of covert U.S. military personnel killed or lost MIA while operating on Studies and Observations Group (SOG) reconnaissance missions in Laos and Cambodia. During the prolonged conflict the Army Special Forces trained regular and paramilitary units of several Allied nations as well as US reconnaissance members; supervised the indigenous Civilian Irregular Defense Group stationed throughout Vietnam in fortified camps and as backup reserves; monitored the border region and infiltration routes; conducted strategic intelligence missions and fielded numerous elements engaged in special operational tasks. From 1957 to 1973, over 20,000 Special Forces soldiers served out of a total of 3.2 million American servicemen, who were deployed throughout the war. Of these 882 died, killed in action or went missing in Southeast Asia (including 121 in Laos and 32 in Cambodia). The "Green Beret Affair": U. S.
Sources: en.wikipedia.org
Lemmon, well aware of Quaalude's public image problems, used advertisements in medical journals to urge physicians "not to permit the abuses of illegal users to deprive a legitimate patient of the drug". Lemmon also marketed a small quantity under another name, Mequin, so doctors could prescribe the drug without the negative connotations. The rights to Quaalude were held by the JB Roerig & Company division of Pfizer, before the drug was discontinued in the United States in 1985, mainly due to its psychological addictiveness, widespread abuse, and illegal recreational use. A 2024 Hungarian investigative documentary reported on large-scale production and sales of the drug by the Hungarian People's Republic to the United States in the 1970s and 1980s. It asserts that a Hungarian state-owned company utilized connections to Colombian drug cartels to facilitate the sale of extraordinary amounts to the United States.
=== Specific === Acetylcysteine Atropine Calcium gluconate Methylthioninium chloride (methylene blue) Naloxone Penicillamine Potassium ferric hexacyano-ferrate(II) -2H2O (prussian blue) Sodium nitrite Sodium thiosulfate Complementary:
Silver nanoparticles are nanoparticles of silver of between 1 nm and 100 nm in size. While frequently described as being 'silver' some are composed of a large percentage of silver oxide due to their large ratio of surface to bulk silver atoms. Numerous shapes of nanoparticles can be constructed depending on the application at hand. Commonly used silver nanoparticles are spherical, but diamond, octagonal, and thin sheets are also common. It is typically used as a colloid, hence the name colloidal silver. Their extremely large surface area permits the coordination of a vast number of ligands. The properties of silver nanoparticles applicable to human treatments are under investigation in laboratory and animal studies, assessing potential efficacy, biosafety, and biodistribution.
Sources: en.wikipedia.org
Legal status varies by country. It is not approved as a medicine, and it is prohibited in sport. Some jurisdictions restrict import, sale, or possession.
Laboratories use liquid chromatography-tandem mass spectrometry to detect GW501516 and its metabolites. Urine is commonly tested, and testing can occur in and out of competition.
No, cardarine is not a SARM. It is a PPARδ agonist, which acts on a different receptor. The two classes are often confused in online discussions.
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.